Analysts Bullish on Arcus Biosciences Stock
December 26, 2022
Trending News 🌥️
Arcus Biosciences ($NYSE:RCUS) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics to address unmet needs in oncology. The company has a portfolio of compounds, including first-in-class small-molecule inhibitors, that are currently in clinical development for a variety of cancer indications. Their current pipeline includes multiple clinical and preclinical programs targeting key oncology pathways, such as checkpoint inhibition, angiogenesis, and immuno-oncology. Analysts have taken a bullish stance on Arcus Biosciences stock. They cite the company’s strong clinical data, promising pipeline, and strategic partnerships as reasons for optimism. Analysts have noted that the company’s drugs could potentially become game-changers in the fight against cancer. Their clinical programs are backed by a knowledgeable and experienced management team, as well as a wide network of strategic collaborations with leading biopharmaceutical companies.
Analysts have also pointed to the company’s financial strength as a strength. Arcus Biosciences has raised over $1 billion in capital to support its research and development efforts. This has enabled the company to invest heavily in its clinical and preclinical programs, giving them the resources necessary to develop treatments that could revolutionize the way cancer is treated. Overall, analysts remain confident in Arcus Biosciences’ ability to bring innovative treatments to market. With an experienced management team, promising pipeline, and strong financial position, analysts believe Arcus Biosciences has the potential to be a leader in oncology research and development in the coming years.
Share Price
On Tuesday, Arcus Biosciences opened at $24.0 and closed at $20.6, plunging by 32.5% from the previous closing price of 30.5. This was in line with the wider market selloff. Analysts remain optimistic about Arcus Biosciences stock, despite the recent plunge in the share price. They point to the company’s strong fundamentals, which include a well-balanced portfolio of products and a strong management team.
Additionally, analysts believe that Arcus Biosciences is well-positioned to benefit from the increasing demand for biopharmaceuticals. Moreover, Arcus Biosciences has a strong pipeline of potential drugs and therapies in development. The results of this trial could prove to be highly lucrative for the company. They believe that the company’s strong fundamentals and pipeline of products should keep the stock well-supported in the long term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Arcus Biosciences. More…
| Total Revenues | Net Income | Net Margin |
| 432.84 | 79.82 | 13.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Arcus Biosciences. More…
| Operations | Investing | Financing |
| 445.64 | -440.9 | 33.48 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Arcus Biosciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.48k | 729.39 | 10.33 |
Key Ratios Snapshot
Some of the financial key ratios for Arcus Biosciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 299.0% | – | 14.3% |
| FCF Margin | ROE | ROA |
| 98.4% | 7.1% | 3.6% |
VI Analysis
Investing in a company requires careful analysis of its fundamentals in order to assess its potential. Fortunately, the VI App simplifies this process. With its Risk Rating, it provides an easy way to evaluate the overall risk of an investment. According to the VI App, ARCUS is a high risk investment in terms of financial and business aspects. The app has identified three risk warnings in the balance sheet, cash flow statement and financial journal of ARCUS. These warnings include: low liquidity, high debt-to-equity ratio, and weak profitability. They suggest that investing in ARCUS could be a risky proposition. Moreover, the VI App also assesses the company’s other financial metrics, such as return on equity (ROE), debt-to-asset ratio, and operating margin. These metrics provide a comprehensive view of the company’s financial health. Overall, the VI App makes it easy to evaluate the potential of a company like ARCUS. By providing a detailed analysis of the company’s fundamentals, it allows investors to make informed decisions. To know more about the warning signals and other features of the app, register with us today. More…
VI Peers
The company’s product candidates include AB928, AB154 and AB122, which are in various clinical trials for the treatment of solid tumors and hematologic malignancies. Arcus Biosciences Inc’s competitors include Immunic Inc, G1 Therapeutics Inc, Ocuphire Pharma Inc.
– Immunic Inc ($NASDAQ:IMUX)
The company’s market cap is $56.93M as of 2022 and its ROE is -44.31%. The company is engaged in the development of immunotherapies for the treatment of cancer.
– G1 Therapeutics Inc ($NASDAQ:GTHX)
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for the treatment of cancer. The company’s lead product candidate is trilaciclib, which is in clinical development for the treatment of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). Trilaciclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that selectively targets proliferating cancer cells and spares normal cells. CDK4/6 inhibitors are a new class of anti-cancer drugs that block the activity of two proteins that are involved in cell division.
G1 Therapeutics has a market cap of $366.9 million and a return on equity of -159.15%. The company’s lead product candidate is trilaciclib, which is in clinical development for the treatment of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). Trilaciclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that selectively targets proliferating cancer cells and spares normal cells. CDK4/6 inhibitors are a new class of anti-cancer drugs that block the activity of two proteins that are involved in cell division.
– Ocuphire Pharma Inc ($NASDAQ:OCUP)
Ocuphire Pharma Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing therapies to treat ocular disorders. Its lead product candidate is Nyxol, a once-daily eye drop for the treatment of glaucoma and ocular hypertension. The company was founded by Derek J. Rappaport and Nancy S. Lurie on March 1, 2006 and is headquartered in Boca Raton, FL.
Summary
Investing in Arcus Biosciences can be a risky proposition due to the company’s relatively recent launch and lack of track record. Despite this, analysts have recently expressed their bullishness on the stock, citing its promising pipeline of cancer therapeutics and the potential for growth in the biopharmaceuticals sector. The current market sentiment for Arcus Biosciences is mostly negative, as the stock price has moved down the same day news coverage was released. This could be a sign of investor uncertainty about the company, and as such taking a position in Arcus Biosciences warrants careful consideration. For those comfortable with the risk of investing in Arcus Biosciences, the upside potential could be significant. The company is developing multiple cancer-fighting drugs that have shown promising results in in-vitro and animal studies. The potential for successful clinical trials and FDA approval could lead to substantial growth for the company. Additionally, the biopharmaceuticals industry is expected to experience strong growth over the next few years, which could provide additional upside for Arcus Biosciences. Ultimately, any potential investor should do their own due diligence and research before making an investment decision.
However, for those willing to take on the risk, Arcus Biosciences could be an intriguing stock worth considering. With its promising pipeline of cancer therapeutics and its potential for growth in a booming industry, investing in Arcus Biosciences could lead to high rewards.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
